Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 104   

Articles published

PSTI 1.93 -0.04 (-2.03%)
price chart
Company Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Drops by -2.94%
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has lost 2.94% during the past week and dropped 17.16% in the last 4 weeks.
Maxim Group Maintains Buy on Pluristem Therapeutics Inc. Following Patent Issuance
In a research report released Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) with an $8.00 price target, after the company announced that the U.S Patent and Trademark Office ...
Pluristem Therapeutics Rating Reiterated by Maxim Group (PSTI)  Dakota Financial News
Pluristem Therapeutics Given Buy Rating at Maxim Group (PSTI)  WKRB News
MLV Offers Commentary on Pluristem Therapeutics Inc. Following Regulatory Updates
In a research report released today, MLV's healthcare analyst Vernon Bernardino reiterated a Buy rating on shares of Pluristem Therapeutics Inc (NASDAQ:PSTI), with a $6 price target, after the company announced that the Japan's Pharmaceuticals and ...
Pluristem Therapeutics' (PSTI) PLX-PAD Cells Granted Safety Clearance in ...  StreetInsider.com
Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in ...  MarketWatch
Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Drops by -6.85%
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has lost 6.85% during the past week and dropped 10.92% in the last 4 weeks.
Pluristem Therapeutics Receives $5.00 Average PT from Analysts (NASDAQ:PSTI)  sleekmoney
Pluristem Therapeutics Inc.'s PLX Cells Get Green Light For Fast Track ...
Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, it appears the fantasy may become reality, featuring Pluristem Therapeutics Inc. (NASDAQ:PSTI) as its ...
Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Drops by -10.04%
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has lost 10.04% during the past week and dropped 10.42% in the last 4 weeks.
Short Interest Update of Pluristem Therapeutics, Inc. (NASDAQ:PSTI)
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) stated loss of 222,269 shares or 23.4% in the short interest. The short interest registered from 951,894 on June 15,2015 to 729,625 on June 30,2015.
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Price Target Update
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) stock has received a short term price target of $ 6 from 2 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $2.83.
Pluristem Therapeutics Announces Pricing of Registered Direct Offering of ...
HAIFA, Israel, June 25, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common stock and warrants to purchase up to 4,080,000 ...